ASCO 2023

CDK4/6i in EBC: Have abema and ribo arrived in the…

Sonia trial: How does the new data change clinical…

Discussions and controversies on social-media: what is…

CDK4/6 inhibitors in EBC: Amazing data, but longer…

Expanding CDK4/6i therapy in EBC: How to select…

PART1: How to de-escalate chemotherapy? What is the…

New data on Ribocilib in adjuvant setting EBC: What…

Chemotherapy de-escalation in HER2+ patients:…

De-escalation of CT for early BC

10 years update on ShortHER

Response adapted, chemotherapy-free option in HER2+ EBC

Practice changing or not quite yet?

PHERGain opens the possibility to avoid chemotherapy in…

Tumor-informed ctDNA likely prognostic for relapse in…

Chemo-immunotherapeutic signals especially in HER2low…

My EBC highlights from ASCO23

TILs are prognostic but not predictive in HER2+ EBC

First data with adjuvant ribociclib

Ribociclib improves iDFS

TILs in HER2+ disease - prognostic, but not enough to…

Checkpoint inhibition in endometrial cancer: new…

Analyses of ctDNA in PENELOPE-B: Test methods are…

Early follow-up shows clear benefit

Can we preserve our patients form chemotherapy?

Palbociclib after Palbociclib might not be the best…

Ovarian function - Ovarian suppression not necessary in…

Discussions on CDK4/6 inhibitors in EBC

From PENELOPE-B to SURVIVE

1/3 of patients with HER2+ in future without…

Young patients benefit from ovarian suppression

Ribociclib has arrived in the adjuvant setting

TILs subtypes are associated with clinical features and…

White blood cells with increasing prognostic relevance?…

A challenge for clinical management

SOC of ovarian ablation confirmed in meta-analysis.

More CDK4/6 options for EBC patients

Von PENELOPE-B zur SURVIVE

Eine Herausforderung für viele Patienten, wenig…

SOC der ovarialen Ablation in der Metaanalyse bestätigt

Primele date cu ribociclib adjuvant

NATALEE nicht überraschend aber überzeugend positiv

1/3 der Patientinnen mit HER2+ zukünftig ohne…

Response adaptierte, Chemotherapie-freie Option beim…

Eine Herausforderung für das klinische Management

TILs Subtypen sind assoziiert mit klinischen Merkmalen…

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…

Kolejny dowód na skuteczność immunoterapii w…

Tumor-informed ctDNA wahrscheinlich prognostisch für…

Ovar Funktion - Ovarielle Supression verzichtbar bei…

Czy wystarczy, aby zmienić standardy?

PHERGain abre la posibilidad de evitar la quimioterapia…

TILs sind prognostisch aber nicht prädiktiv beim HER2+…

I miei punti salienti di ASCO23

Palbociclib después de Palbociclib podría no ser la…

E-Health Applications in Oral Cancer Therapy

Molecular imaging for endocrine responsivness

Updates on ADCs in metastatic breast cancer

The start of precision medicine in HR+ breast cancer

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

What is the optimal therapie sequence for HR+ MBC…

Mises à jour sur les ADC dans le cancer du sein…

Aggiornamenti sugli ADC nel carcinoma mammario…

The value of eHealth

CDK4/6i in first line and beyond & Biomarkers

Update ADC efficacy

ARASEC: ADT + Daralutamide for mHSPC

Over-staging of bone scan compared with PSMA PET/CT

Metastasis-directed for prostate cancer

Confirming results for PARPi in mCRPC

DEAR trial: real-world comparator analyses of ARIs

AI for prediction in local prostate carcinoma

PSA nadir 6 month after Radiotherapy is strong…

Intensified or de-intensified therapy in mHSPC

PRL-02: Intramuscular arbiraterone

TALAPRO-2: Results and controversies

Part2: Important update on testosterone-recovery

Reassuring real-world data!

PAPR-inhibitors: Patient-selection matters!

LuPARP combination study: LuPSMA and Olaparib in mCRPC

Part 1: Important update on testosterone-recovery

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

PSA nadir 6 månader efter radioterapi är en prognostisk…

PARP-inhibitors: La selección de pacientes es…

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

PARPi in PCa: more genetic testing is required as PRO…

What is your preferred sequence in 1st line treatment…

Q-TWiST in the therapy of aUC

Best of Bladder: ddMVC increases DFS! Standard…

Enfortumab vedotin + pembrolizumab 1stL in…

Extent of lymphadenectomy in cystectomy

New standard for MIBC

FGFR inhibition

First line in cisplatin-ineligible advance urothelial…

Targeted therapies in advanced urothelial cancer: The…

New SoC option for metastatic bladder cancer

Best of Bladder: ddMVC increases DFS! Standard…

Nouvelles options de soins standard pour le cancer de…

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El…

Update EV/Pembro, Avelumab Maintenance

The efficacy of FGFR targeting

The impact of microbiome and supplements on therapy…

Long term follow up in advanced renal cell cancer: Is…

Non ccRCC: how should we treat patients today?

1st Line therapy RCC: which combination to choose?

New standard for 2nd line RCC?

News from the adjuvant

Update and take home message of 1st Line mRCC

Lenvatinib + pembrolizumab in non-clear cell renal cell…

New data non ccRCC

IO rechallenge in mRCC

The value of perioperative chemo-IO in rNSCLC and the…

EGFR testing necessary in the adjuvant setting

Added benefit of perioperative chemo/IO in stage 2-3b…

A new standard of care

Which should we prefer: neoadjuvant, adjuvant or…

ADAURA - results and controversies

A new standard of care for operated patients with…

An imperfect analysis, but perfect results

CheckMate 9LA: 4‑year clinical update

Adjuvant IO in KRASm patients

ADAURA - Discussion closed?

A chemo-free preop. IO strategy?

Adjuvant and neoadjuvant strategies in resectable NSCLC

Induction options in the perioperative setting

Perioperative treatment

Role of periopertative IO confirmed

Confirmation of neoadjuvant immunotherapy

OS benefit from EGFR receptor TKI

Another neoadjuvant chemo/IO option

Un nouveau standard therapeutique pour les patients…

Más opciones en el entorno perioperatorio

Que devrions-nous préférer: traitement néoadjuvant,…

ADAURA- discussie gesloten?

Stratégies adjuvantes et néoadjuvantes dans le CBNPC…

Rolle der periopertativen IO bestätigt

Zorifertinib: an option when osimertinib is not…

Update on KRASG12Cm treatment options - how to proceed?

TTF-treatment requires further studies

Pembro + chemo in pts with TKI-resistant EGFRm /…

Does ADC + chemo + IO replace the existing concepts?

ADC + ICI ± Pt-CT in patients with aNSCLC

TROP2-ADC shows high response rates in 1L-combination…

CORRELATE - a real world analysis

IO in EGRF positive patients post TKI

Stopping treatment is ok

New data from another BiTE

More BiTEs, more possibilities

Hyperfractionated radiotherapy for SCLC

Can we incoporate biomarkers in SCLC treatment?

A positive trial with no impact

Más BiTEs, más posibilidades

Stratégies de traitement dans le SCLC

No practice-changing data in mesothelioma, other…

Immune checkpoint inhibitors in malignant mesothelioma